Title :

A Double-Blind, Randomized, Placebo-Controlled Trial of Bumetanide in Parkinson's Disease

Author(s) :

Damier, Philippe [Auteur]
Centre d'investigation clinique (CIC) de Nantes -CIC Plurithématique [CIC 0004 - Nantes]
Degos, Bertrand [Auteur]
Hôpital Avicenne [AP-HP]
Castelonovo, Giovanni [Auteur]
Centre Hospitalier Universitaire de Nîmes [CHU Nîmes]
Anheim, Mathieu [Auteur]
Fédération de Médecine Translationnelle de Strasbourg [FMTS]
Benatru, Isabelle [Auteur]
CIC Poitiers – Centre d'investigation clinique de Poitiers [CIC 1402]
Carrière, Nicolas [Auteur]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Colin, Olivier [Auteur]
Centre Hospitalier de Brive-la-Gaillarde [CH Brive]
Defebvre, Luc [Auteur]
Lille Neurosciences & Cognition (LilNCog) - U 1172
Deverdal, Marie [Auteur]
Centre Hospitalier Universitaire de Nîmes [CHU Nîmes]
Eusebio, Alexandre [Auteur]
Aix Marseille Université [AMU]
Ferrier, Vanessa [Auteur]
Service de Neurologie [CHU Nice]
Giordana, Caroline [Auteur]
Service de Neurologie [CHU Nice]
Houeto, Jean-Luc [Auteur]
Epidémiologie des Maladies Chroniques en zone tropicale [EpiMaCT]
Le Dily, Severine [Auteur]
Centre d'investigation clinique (CIC) de Nantes -CIC Plurithématique [CIC 0004 - Nantes]
Mongin, Marie [Auteur]
Sorbonne Université [SU]
Thiriez, Claire [Auteur]
Service de Neurologie [CHU Caen]
Tranchant, Christine [Auteur]
Fédération de Médecine Translationnelle de Strasbourg [FMTS]
Service de Neurologie [Strasbourg]
Ravel, Denis [Auteur]
Corvol, Jean-Christophe [Auteur]
Institut du Cerveau = Paris Brain Institute [ICM]
Sorbonne Université [SU]
CHU Pitié-Salpêtrière [AP-HP]
Rascol, Olivier [Auteur]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Ben Ari, Yehezkel [Auteur]

Journal title :

Movement Disorders

Abbreviated title :

Mov Disord

Volume number :

39

Pages :

618-622

Publisher :

Wiley

Publication date :

2024-01-30

ISSN :

1531-8257

English keyword(s) :

bumetanide
GABAergic cells
NKCC1 inhibitor
Parkinson’s disease

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Background : Acting on the main target of dopaminergic cells, the striatal γ-aminobutyric acid (GABA)-ergic cells, might be a new way to treat persons with Parkinson's disease (PD). Objective : The objective of this ...
Show more >Background : Acting on the main target of dopaminergic cells, the striatal γ-aminobutyric acid (GABA)-ergic cells, might be a new way to treat persons with Parkinson's disease (PD). Objective : The objective of this study was to assess the efficacy of bumetanide, an Na–K–Cl cotransporter (NKCC1) inhibitor, to improve motor symptoms in PD. Methods : This was a 4-month double-blind, randomized, parallel-group, placebo-controlled trial of 1.75 to 3 mg/day bumetanide as an adjunct to levodopa in 44 participants with PD and motor fluctuations. Results : Compared to the baseline, the mean change in OFF Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III score after 4 months of treatment (primary endpoint) did not improve significantly compared with placebo. No changes between participants treated with bumetanide and those treated with placebo were observed for most other outcome measures. Despite no relevant safety signals, bumetanide was poorly tolerated. Conclusions : There was no evidence in this study that bumetanide has efficacy in improving motor symptoms of PD. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.Show less >

Language :

Anglais

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Lille Neurosciences & Cognition (LilNCog) - U 1172

Research team(s) :

Troubles cognitifs dégénératifs et vasculaires

Submission date :

2024-02-06T23:12:09Z
2024-06-18T15:56:15Z